Latest 5-Hydroxyindoleacetic acid Stories
THE WOODLANDS, Texas, Aug. 9, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, July 21 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, July 7 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, a biopharmaceutical company, has successfully completed a second Phase I clinical trial of LX1032, an orally-delivered small molecule drug candidate for managing gastrointestinal symptoms associated with carcinoid syndrome.
* Drug Candidate Will Advance to Phase 2 Clinical Trial in Carcinoid Patients * Potent Reduction in Serotonin Achieved * Drug Candidate Being Developed Under Fast Track Status From FDA THE WOODLANDS, Texas, Nov. 13, 2008 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.
- A morbid dread of being buried alive. Also spelled 'taphiphobia'.